Phio Pharmaceuticals Corp (PHIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Phio Pharmaceuticals Corp (PHIO) has a cash flow conversion efficiency ratio of -0.243x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.00 Million) by net assets ($16.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Phio Pharmaceuticals Corp defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Phio Pharmaceuticals Corp - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Phio Pharmaceuticals Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Phio Pharmaceuticals Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Phio Pharmaceuticals Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NFL Biosciences SAS
PA:ALNFL
|
0.032x |
|
Lanthanein Resources Ltd
AU:LNR
|
-0.019x |
|
Personas Social Inc
V:PRSN
|
-0.185x |
|
Waja Konsortium Bhd
KLSE:0102
|
-0.118x |
|
Hawsons Iron Ltd
AU:HIO
|
-0.015x |
|
E-Starco
KO:015020
|
0.037x |
|
Draper Esprit PLC
LSE:GROW
|
-0.016x |
|
Magna Terra Minerals Inc
V:MTT
|
-0.282x |
Annual Cash Flow Conversion Efficiency for Phio Pharmaceuticals Corp (2011–2025)
The table below shows the annual cash flow conversion efficiency of Phio Pharmaceuticals Corp from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see PHIO market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $20.15 Million | $-7.98 Million | -0.396x | +73.70% |
| 2024-12-31 | $4.72 Million | $-7.11 Million | -1.506x | -8.29% |
| 2023-12-31 | $7.73 Million | $-10.75 Million | -1.391x | -24.28% |
| 2022-12-31 | $10.84 Million | $-12.13 Million | -1.119x | -106.95% |
| 2021-12-31 | $21.93 Million | $-11.86 Million | -0.541x | +20.04% |
| 2020-12-31 | $13.02 Million | $-8.80 Million | -0.676x | +55.04% |
| 2019-12-31 | $5.75 Million | $-8.64 Million | -1.504x | -171.56% |
| 2018-12-31 | $13.58 Million | $-7.52 Million | -0.554x | +89.33% |
| 2017-12-31 | $1.83 Million | $-9.51 Million | -5.190x | -626.05% |
| 2016-12-31 | $10.86 Million | $-7.76 Million | -0.715x | +13.14% |
| 2015-12-31 | $8.89 Million | $-7.32 Million | -0.823x | +70.88% |
| 2014-12-31 | $2.75 Million | $-7.76 Million | -2.826x | -121.32% |
| 2013-12-31 | $4.94 Million | $-6.31 Million | -1.277x | -247.33% |
| 2012-12-31 | $-5.84 Million | $-5.06 Million | 0.867x | -94.91% |
| 2011-12-31 | $-587.00K | $-9.99 Million | 17.017x | -- |
About Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene ex… Read more